Eris Biotech

Eris Biotech is a private, preclinical-stage biotech targeting a fundamental challenge in oncology: immune evasion. The company's core asset is a first-in-class, oral small-molecule inhibitor designed to reawaken the immune system against cancer by blocking a specific evasion pathway, distinct from checkpoint inhibitors. This mechanism, which is not dependent on a single protein target, could offer a safer, more convenient treatment option with applicability across a wider range of patients. Backed by undisclosed investors, the company is positioned in the competitive but high-potential field of next-generation immuno-oncology.

Discovery platform focused on identifying and targeting novel immune evasion pathways in cancer, leading to the development of oral small-molecule inhibitors that do not rely on traditional protein targets.

Eris operates in the highly competitive next-generation immuno-oncology field, competing against large pharma and numerous biotechs developing novel immune modulators, cell therapies, and cancer vaccines. Its differentiation hinges on the novelty of its pathway and the convenience of an oral small-molecule format.